Lumos Pharma: Updated 12 and 24-Mo Data From Phase 2 OraGrowtH210 and OraGrowtH212 Trials Show Oral LUM-201 Achieves Significant Increase in Growth >LUMO
Lumos Pharma: Updated 12 and 24-Mo Data From Phase 2 OraGrowtH210 and OraGrowtH212 Trials Show Oral LUM-201 Achieves Significant Increase in Growth >LUMO
Lumos Pharma：来自第二阶段 oraGrowth210 和 OraGrowth212 试验的最新的 12 个月和 24 个月数据显示，口服 LUM-201 的生长显著增加 >LUMO
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册